

Supplementary Table S1. Medication background of the two groups at baseline.

Therapeutic intervention	Total (n=170)		χ^2	p-value
	anti-Ro52 antibody positive (n=112)	anti-Ro52 antibody negative (n=58)		
IVIg, n (%)	15 (13.4)	7 (12.1)	0.059	0.807
Plasmapheresis, n (%)	0	2 -	-	-
High dose GC Puls, n (%)	4 (3.6)	1 (1.7)	0.04639	0.844
GC dosage in the beginning for ≥ 2 mg/kg/days, n (%)	6 (5.4)	5 (8.6)	0.672	0.412
GC dosage in the beginning for $>1-2$ mg/kg/days, n (%)	31 (27.7)	14 (24.1)	0.246	0.620
GC dosage in the beginning for ≤ 1 mg/kg/days, n (%)	52 (46.4)	23 (39.7)	0.711	0.399
Biologicals or Targeted therapy*, n (%)	7 (6.3)	3 (5.2)	0.000	1.000
CsA, n (%)	12 (10.7)	2 (3.4)	1.795	0.180
Thalidomide, n (%)	2 (1.8)	1 (1.7)	0.000	1.000
Tac, n (%)	9 (8.0)	8 (9.4)	1.407	0.235
CYC, n (%)	15 (13.4)	14 (12.5)	3.118	0.077
AZA, n (%)	5 (4.5)	3 (5.2)	0.000	1.000
MTX, n (%)	3 (2.7)	3 (5.2)	0.158	0.691
IGU, n (%)	0	2 -	-	-
HCQ, n (%)	2 (1.8)	1 (1.7)	0.000	1.000
MMF, n (%)	0	1 -	-	-
Antibiotic used, n (%)	52 (46.4)	24 (41.4)	0.394	0.530
Antifungal drugs used, n (%)	8 (7.1)	7 (6.3)	1.153	0.283

Dichotomous variables were represented as count (percentage).

High dose GC Puls was defined as GC dosage greater than 500 mg methylprednisolone per day.

IVIg: intravenous immunoglobulin; GC: glucocorticoid; CsA: cyclosporine A; Tac: tacrolimus; CYC: cyclophosphamide; AZA: azathioprine; MTX: methotrexate; IGU: iguratimod; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil.

*Including tofacitinib, tumour necrosis factor- α inhibitor and tocilizumab.

Supplementary Table S2. Treatment of both groups at the last visit (drugs that were replaced during the course of the disease are not included).

Therapeutic intervention	Total (n=170)		χ^2	p-value
	anti-Ro52 antibody positive (n=112)	anti-Ro52 antibody negative (n=58)		
IVIg, n (%)	19 (17.0)	18 (31.0)	4.443	0.035*
High dose GC Puls, n (%)	1 (0.9)	4 (6.9)	2.992	0.084
GC dosage in the beginning for ≥ 2 mg/kg/days, n (%)	15 (13.4)	7 (12.1)	0.059	0.807
GC dosage in the beginning for $>1-2$ mg/kg/days, n (%)	52 (46.4)	23 (39.7)	0.711	0.399
GC dosage in the beginning for ≤ 1 mg/kg/days, n (%)	38 (33.9)	15 (25.9)	1.159	0.282
Biologicals or Targeted therapy*, n (%)	4 (3.6)	5 (8.6)	1.066	0.302
CsA, n (%)	21 (18.8)	4 (6.9)	3.387	0.039*
Thalidomide, n (%)	1 (0.9)	1 (1.7)	0.000	1.000
Tac, n (%)	27 (24.1)	7 (12.1)	3.461	0.063
CYC, n (%)	4 (3.6)	5 (8.6)	1.066	0.302
AZA, n (%)	7 (6.3)	3 (5.2)	0.000	1.000
MTX, n (%)	2 (1.8)	3 (5.2)	0.578	0.447
IGU, n (%)	3 (2.7)	1 (1.7)	0.000	1.000
HCQ, n (%)	2 (1.8)	1 (1.7)	0.000	1.000
MMF, n (%)	6 (5.4)	2 (3.4)	0.031	0.861
LEF, n (%)	0	4 -	0.013	0.013
Antibiotic used, n (%)	48 (42.9)	24 (41.4)	0.034	0.853
Antifungal drugs used, n (%)	43 (38.4)	18 (31.0)	0.899	0.343
Nintedanib, n (%)	7 (6.3)	2 (3.4)	0.170	0.680
Pirfenidone, n (%)	27 (24.1)	10 (17.2)	1.058	0.304

Dichotomous variables were represented as count (percentage).

High dose GC Puls was defined as GC dosage greater than 500 mg methylprednisolone per day.

IVIg: intravenous immunoglobulin; GC: glucocorticoid; CsA: cyclosporine A; Tac: tacrolimus; CYC: cyclophosphamide; AZA: azathioprine; MTX: methotrexate; IGU: iguratimod; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil.

*Including tofacitinib, tumour necrosis factor- α inhibitor and tocilizumab.

IQR: interquartile range; FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide; UIP: usual interstitial pneumonia; NSIP: non-specific interstitial pneumonia; LIP: lymphocytic interstitial pneumonia; OP: organizing pneumonia; CRP: C reactive protein; SF: serum ferritin; LDH: lactate dehydrogenase; IgG: immunoglobulin G.